Xvivo Perfusion AB (publ)
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- $296.96 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Xvivo Perfusion AB (publ) had its IPO on under the ticker symbol XVIPY.
The company operates in the sector and industry. Xvivo Perfusion AB (publ) has a staff strength of 133 employees.
Shares of Xvivo Perfusion AB (publ) opened at $6 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $6 - $6, and closed at $6.
This is a +29.87% increase from the previous day's closing price.
A total volume of 650 shares were traded at the close of the day’s session.
In the last one week, shares of Xvivo Perfusion AB (publ) have increased by 0%.
Xvivo Perfusion AB (publ)'s Key Ratios
Xvivo Perfusion AB (publ) has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Xvivo Perfusion AB (publ)’s revenue was $0 with a gross profit of $296.96 million and an EBITDA of $0. The EBITDA ratio measures Xvivo Perfusion AB (publ)'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Xvivo Perfusion AB (publ)’s operating margin was 0% while its return on assets stood at 0.57% with a return of equity of 1.36%.
In Q3, Xvivo Perfusion AB (publ)’s quarterly earnings growth was a negative -95.1% while revenue growth was a positive 53.2%.
Xvivo Perfusion AB (publ)’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Xvivo Perfusion AB (publ)’s profitability.
Xvivo Perfusion AB (publ) stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Xvivo Perfusion AB (publ) stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- Total Liabilities
- $86.37 million
- Operating Cash Flow
- Capital Expenditure
- $6.10 million
- Dividend Payout Ratio
Xvivo Perfusion AB (publ) ended 2023 with $0 in total assets and $0 in total liabilities. Its intangible assets were valued at $0 while shareholder equity stood at $0.
Xvivo Perfusion AB (publ) ended 2023 with $523.50 million in deferred long-term liabilities, $86.37 million in other current liabilities, 756000.00 in common stock, $27.02 million in retained earnings and $0 in goodwill. Its cash balance stood at $0 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Xvivo Perfusion AB (publ)’s total current assets stands at $505.98 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $101.42 million compared to accounts payable of $0 and inventory worth $90.00 million.
In 2023, Xvivo Perfusion AB (publ)'s operating cash flow was $-33723000.00 while its capital expenditure stood at $6.10 million.
Comparatively, Xvivo Perfusion AB (publ) paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Xvivo Perfusion AB (publ) stock is currently trading at $6 per share. It touched a 52-week high of $6 and a 52-week low of $6. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.